Biophagy is awarded a second NMSBA leverage grant with Sandia National Laboratories to lead a team of three companies (including Avisa Pharma and Omphalos Biosciences) towards identifying a lead autophagy stimulant in tuberculosis. The team will be working with human TB bacteria (M. tuberculosis, attenuated) and human macrophages to determine the effects of autophagy on isoniazid antibiotic enhancement and on U-TAID (proprietary antibiotic). They will also use an siRNA knockdown cell line to delineate the direct role of autophagy in compound activity and antibiotic enhancement.
Leave A Comment